Advertisement

Innovative Pediatric Formulations: Ibuprofen in Chocolate-Coated Honey Core

  • Maria S. Synaridou
  • Anne K. Morichovitou
  • Catherine K. MarkopoulouEmail author
Original Article
  • 32 Downloads

Abstract

Purpose

The pediatric population is represented by a diverse group of patients and, as a consequence, additional factors and parameters determining their dosage and taste must be taken into account. The aim of this work is to prepare and analyze an innovative chewable solid drug formulation that would appeal to pediatric patients. In particular, the present study presents a new taste masking processing wherein the drug’s disagreeable taste and the associated unpleasant throat burning sensation are covered with honey and chocolate.

Methods

Ibuprofen was used as the active pharmaceutical ingredient dispersed in formula after being suitably pretreated. Honey and agar are the two main excipients of the formulation while the new pharmaceutical preparation is further coated with milk chocolate to mask its bitter taste. Vitamins A and E were also added in a separate formula as an alternative choice which, apart from the curative action of ibuprofen, display additional benefits. During the development of the analytical methods, liquid/solid and solid phase extraction was performed. Moreover, for the chromatographic determination, a RP-C18 column and two different mobile phases containing acetonitrile and phosphate buffer were used.

Results

The methods were validated on the basis of international guidelines. The recoveries of the active ingredients were 97–102% while the RSD values were 0.06–0.53%. The new preparation was found to be stable for at least 1 year.

Conclusions

Considering children’s difficulty in swallowing medicines with a bitter taste, palatable ibuprofen formulations were made. Their preparative and analytic methods were validated according to ICH guidelines.

Keywords

Pediatric medicines Honey Milk chocolate Vitamin A Vitamin E Ibuprofen 

Notes

Supplementary material

12247_2019_9389_MOESM1_ESM.docx (15 kb)
ESM 1 (DOCX 15 kb)
12247_2019_9389_Fig10_ESM.png (504 kb)
Supplementary Figure 1

(PNG 503 kb)

12247_2019_9389_MOESM2_ESM.tiff (379 kb)
High resolution image (TIFF 378 kb)
12247_2019_9389_Fig11_ESM.png (17 kb)
Supplementary Figure 2

(PNG 16 kb)

12247_2019_9389_MOESM3_ESM.tiff (45 kb)
High resolution image (TIFF 45 kb)
12247_2019_9389_Fig12_ESM.png (30 kb)
Supplementary Figure 3

(PNG 30 kb)

12247_2019_9389_MOESM4_ESM.tiff (41 kb)
High resolution image (TIFF 40 kb)
12247_2019_9389_Fig13_ESM.png (77 kb)
Supplementary Figure 4

(PNG 76 kb)

12247_2019_9389_MOESM5_ESM.tiff (100 kb)
High resolution image (TIFF 100 kb)
12247_2019_9389_MOESM6_ESM.docx (14 kb)
Supplementary Table 1 (DOCX 13 kb)
12247_2019_9389_MOESM7_ESM.docx (15 kb)
Supplementary Table 2 (DOCX 14 kb)

References

  1. 1.
    Mennella JA, Pepino MY, Reed DR. Genetic and environmental determinants of bitter perception and sweet preferences. Pediatrics. 2005;115(2):216–22.CrossRefGoogle Scholar
  2. 2.
    RegulationECNo.1901/2006, http://eurlex.europa.eu/LexUriServ/LexUriServ.do/ uri=OJ:L:2006:378:0001:0019, 2013.
  3. 3.
    Mennella JA, Beauchamp GK. Optimizing oral medications for children. Clin.Ther. 2008;30:2120–32.CrossRefGoogle Scholar
  4. 4.
  5. 5.
    Abraham J, Flowerlet M. Taste masking of peadiatric formulation: a review on technologies, recent trends and regulatory aspects. Int J Pharm Pharm Sci. 2014;6:1.Google Scholar
  6. 6.
    Walsh J, Cram A, Woertz K, Breitkreutz J, Winzenburg G, Turner R, et al. On behalf of the European Formulation Initiative (EuPFI): playing hide and seek with poorly tasting paediatric medicines: do not forget the excipients. Adv Drug Deliv Rev. 2014;73:14–33.Google Scholar
  7. 7.
    Reiland Thomas L, Lipari John M. Encyclopedia of pharmaceutical technology. 3rd ed: Flavours and flavor modifiers. p. 1763–72.Google Scholar
  8. 8.
    Sharma S, Lewis S. Taste masking technologies: a review. Int J Pharm Pharm Sci. 2010;2(2):6–13.Google Scholar
  9. 9.
    Lieberman HA, Lachman L. Chewable tablets. In: Pharmaceutical dosage forms, vol. 1. New York: Marcel Dekker Inc; 1981. p. 387–91.Google Scholar
  10. 10.
    Roy G. Modifying bitterness, Technomic Publishing Co, London England; 1997. p. 179-211.Google Scholar
  11. 11.
    tripithi A, parmar D, patel U, patel G. Taste masking: novel approach for bitter and obnoxious drugs. JPSBR. 2011;1(3):136–42.Google Scholar
  12. 12.
    Deasy. Ion exchange resin in microencapsulation. Newyork: Marcel Dekker Inc; 1980. p. 150.Google Scholar
  13. 13.
    Wehling F., Schuehle S. Effervescent dosage forms with microparticles. US Patent 5,178,878, 1993.Google Scholar
  14. 14.
    Sohi H, Sultana Y, Khar RK. Taste masking technologies in oral pharmaceuticals: recent developments and approaches. Drug Dev Ind Pharm. 2004;30:429–48.CrossRefGoogle Scholar
  15. 15.
    Depalmo GA. Composition based on ibuprofen, for oral usage. Eur Pat Appl. 1993;EP0560207.Google Scholar
  16. 16.
    Lankford BL, Becker CH. The use of some imitation flavors for masking distasteful drugs. I. Ammonium chloride. J Am Pharm Assoc. 1951;XL(2):77–82.CrossRefGoogle Scholar
  17. 17.
    Ueki T., Kameda S., Uno D., Kaneko K. Dentifrices composition. JP 05,155,744, June 22, 1993.Google Scholar
  18. 18.
    Fuisz R. C. Taste masking of pharmaceutical floss with phenol. US Patent 5,028,632, July 2, 1991.Google Scholar
  19. 19.
    Palace V, Khaper N, Qin Q, Singal P. Antioxidant potentials of vitamin A and carotenoids and their relevance to heart disease. Free Radic Biol Med. 1999;26, Issues(5–6):746–61.CrossRefGoogle Scholar
  20. 20.
    Herrera E, Barbas C. Vitamin E: action, metabolism and perspectives. J Physiol Biochem. 2011;57(1):43–56.CrossRefGoogle Scholar
  21. 21.
    Eraga SO, Arhewoh MI, Chibuogwu RN, Iwuagwu MA. A comparative UV−HPLC analysis of ten brands of ibuprofen tablets. Asian Pac J Trop Biomed. 2015;5(10):880–4.CrossRefGoogle Scholar
  22. 22.
    Huidobro AL, Rupérez FJ, Barbas C. Tandem column for the simultaneous determination of arginine, ibuprofen and related impurities by liquid chromatography. J Chromatogr A. 2006;1119(1–2, 30):238–45.CrossRefGoogle Scholar
  23. 23.
    Moreno P, Salvadó V. Determination of eight water- and fat-soluble vitamins in multi-vitamin pharmaceutical formulations by high-performance liquid chromatography. J Chromatogr A. 2000;870(1–2):207–15.CrossRefGoogle Scholar
  24. 24.
    Woollarda DC, Bensch A, Indyk H, Mahon AM. Determination of vitamin A and vitamin E esters in infant formulae and fortified milk powders by HPLC: use of internal standardization. Food Chem. 2016;197:457–65.CrossRefGoogle Scholar
  25. 25.
    Plozza T, Trenerry VC, Caridi D. The simultaneous determination of vitamins A, E and β-carotene in bovine milk by high performance liquid chromatography–ion trap mass spectrometry (HPLC–MSn). Food Chem. 2012;134(1):559–63.CrossRefGoogle Scholar
  26. 26.
    Gleize B, Stei M, André M, Reboul E. Simple and fast HPLC method for simultaneous determination of retinol, tocopherols, coenzyme Q10 and carotenoids in complex samples. Food Chem. 2012;134(4):2560–4.CrossRefGoogle Scholar
  27. 27.
    Mata-Granados JM, de Castro ML, Quesada JM. Fully automated method for the determination of 24,25(OH)2 and 25(OH) D3 hydroxyvitamins, and vitamins A and E in human serum by HPLC. J Pharm Biomed Anal. 2004;35(3):575–82.CrossRefGoogle Scholar
  28. 28.
  29. 29.
    Popescu M. C., Mertz E. T. Taste moderating pharmaceutical. US Patent 5,009,819, April 23, 1991.Google Scholar
  30. 30.
    Kurtz R. J., Fuller W. D. Ingestibles containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers. US Patent 5,232,735, 1993.Google Scholar
  31. 31.
    Nakov N, Petkovska R, Ugrinova L, Kavrakovski Z, Dimitrovska A, Svinarov D. Critical development by design of a rugged HPLC-MS/MS method for direct determination of ibuprofen enantiomers in human plasma. J Chromatogr B. 2015;992(15):67–75.CrossRefGoogle Scholar
  32. 32.
    Reddy YR, Kumar KK, Mukkanti K, Reddy MRP. RP-UPLC method development and validation for the simultaneous estimation of ibuprofen and famotidine in pharmaceutical dosage form. Pharm Methods. 2012;3(2):57–61.CrossRefGoogle Scholar
  33. 33.
    Naidong W, Lee JW. Development and validation of a liquid chromatographic method for the quantitation of ibuprofen enantiomers in human plasma. J Pharm Biomed Anal. 1994;12(4):551–6.CrossRefGoogle Scholar
  34. 34.
    Bonato PS, Perpetua M, Lama F, de Carvalho R. Enantioselective determination of ibuprofen in plasma by high-performance liquid chromatography–electrospray mass spectrometry. J Chromatogr B. 2003;796(2):413–20.CrossRefGoogle Scholar
  35. 35.
    https://en.wikipedia.org/wiki/IbuprofenGoogle Scholar
  36. 36.
    Adams SS. The propionic acids: a personal perspective. J Clin Pharmacol. 1992;32(4):317–23.CrossRefGoogle Scholar
  37. 37.
    Rainsford KD. Ibupropfen, a critical bibliographic review: Tailor and Francis; 2005.Google Scholar
  38. 38.
    Walter K, Weiss G, Laichern A, Stanislaus F. Pharmacokinetics of ibuprofen following a single administration of a suspension containing enteric-coated microcapsules, pubmed.gov, 1995.Google Scholar
  39. 39.
    Urvi G, Harsh C. Taste masking in pharmaceutical industry. Am Pharm Rev. 2014.Google Scholar
  40. 40.
    Breslin PA, Gingrich TN, Green BG. Ibuprofen as a chemesthetic stimulus: evidence of a novel mechanism of throat irritation. Chem Senses. 2001;26:55–65.CrossRefGoogle Scholar
  41. 41.
    Hu Y, Pan J, Liao W, Li J, Gruget P, Kitts D, et al. Determination of antioxidant capacity and phenolic content of chocolate by attenuated total reflectance-Fourier transformed-infrared spectroscopy. Food Chem. 2016;202:254–61.Google Scholar
  42. 42.
    ICH. Harmonized tripartite guideline: validation of analytical procedures: text and methodology Q2(R1). 4th ed: EMEA; 2006.Google Scholar
  43. 43.
    US Pharmacopoeia (USP 29), Ibuprofen tablets.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Maria S. Synaridou
    • 1
  • Anne K. Morichovitou
    • 1
  • Catherine K. Markopoulou
    • 1
    Email author
  1. 1.Laboratory of Pharmaceutical Analysis, Department of Pharmaceutical Technology, School of Pharmacy, Faculty of Health SciencesAristotle University of ThessalonikiThessalonikiGreece

Personalised recommendations